Register
Dupilumab gets FDA nod for moderate-to-severe eczema in teens |
News and Updates
eMediNexus Coverage from: 
Dupilumab gets FDA nod for moderate-to-severe eczema in teens
eMediNexus,  14 March 2019
remove_red_eye 511 Views
#Allergy and Immunology #Dermatology #Pharmacist

0 Read Comments                

The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent, Sanofi/Regeneron) for adolescents aged 12 to 17 years with moderate-to-severe atopic dermatitis poorly controlled with topical prescription therapies or when those therapies are not advisable. It can be used with or without topical corticosteroids.
To continue reading this article
Sign in with Medtalks

Continue reading your article with a eMediNexus account.
Free Membership!